mm1313亚洲精品,欧美俄罗斯40老熟妇,欧美日韩在线观看视频在线,亚洲欧美国产激情综合在线

掃碼關(guān)注公眾號(hào)           掃碼咨詢技術(shù)支持           掃碼咨詢技術(shù)服務(wù)
  
客服熱線:400-901-9800  客服QQ:4009019800  技術(shù)答疑  技術(shù)支持  質(zhì)量反饋  人才招聘  關(guān)于我們  聯(lián)系我們
伊人久久大香线蕉综合影视,东京干一区二区三区欧美
Rabbit Anti-PALB2/Cy5.5 Conjugated antibody (bs-0588R-Cy5.5)
訂購(gòu)熱線:400-901-9800
訂購(gòu)郵箱:sales@www.p2b3.cn
訂購(gòu)QQ:  400-901-9800
技術(shù)支持:techsupport@www.p2b3.cn
說 明 書: 100ul  
100ul/2980.00元
大包裝/詢價(jià)
產(chǎn)品編號(hào) bs-0588R-Cy5.5
英文名稱1 Rabbit Anti-PALB2/Cy5.5 Conjugated antibody
中文名稱 Cy5.5標(biāo)記的乳腺癌易感基因相關(guān)蛋白2
別    名 DKFZp667I166; 4732427B05; BC066140; DKFZp686E1054; FANCN; FANCN GENE; FLJ21816; OTTMUSP00000025884; PALB2; partner and localizer of BRCA2; RGD1304759; PALB2_HUMAN.  
規(guī)格價(jià)格 100ul/2980元 購(gòu)買        大包裝/詢價(jià)
說 明 書 100ul  
研究領(lǐng)域 腫瘤  神經(jīng)生物學(xué)  信號(hào)轉(zhuǎn)導(dǎo)  細(xì)胞凋亡  
抗體來源 Rabbit
克隆類型 Polyclonal
交叉反應(yīng) Human, Pig,  (predicted: Mouse, Rat, Cow, )
產(chǎn)品應(yīng)用 Flow-Cyt=1:50-200 IF=1:50-200 
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 131kDa
性    狀 Lyophilized or Liquid
濃    度 1mg/ml
免 疫 原 KLH conjugated synthetic peptide derived from human PALB2 C-terminus
亞    型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
產(chǎn)品介紹 background:
This gene encodes a protein that may function in tumor suppression. This protein binds to and colocalizes with the breast cancer 2 early onset protein (BRCA2) in nuclear foci and likely permits the stable intranuclear localization and accumulation of BRCA2. Essential partner of BRCA2 that promotes the localization and stability of BRCA2. Also enables its recombinational repair and checkpoint functions of BRCA2. May act by promoting stable association of BRCA2 with nuclear structures, allowing BRCA2 to escape the effects of proteosome-mediated degradation.

Function:
Plays a critical role in homologous recombination repair (HRR) through its ability to recruit BRCA2 and RAD51 to DNA breaks. Serves as the molecular scaffold in the formation of the BRCA1-PALB2-BRCA2 complex which is essential for homologous recombination. Strongly stimulates the DNA strand-invasion activity of RAD51, stabilizes the nucleoprotein filament against a disruptive BRC3-BRC4 polypeptide and helps RAD51 to overcome the suppressive effect of replication protein A (RPA). Functionally cooperates with RAD51AP1 in promoting of D-loop formation by RAD51. Essential partner of BRCA2 that promotes the localization and stability of BRCA2. Also enables its recombinational repair and checkpoint functions of BRCA2. May act by promoting stable association of BRCA2 with nuclear structures, allowing BRCA2 to escape the effects of proteasome-mediated degradation. Binds DNA with high affinity for D loop, which comprises single-stranded, double-stranded and branched DNA structures.

Subunit:
Homooligomer. Oligomerization is essential for its focal accumulation at DNA breaks. Part of a trimeric complex containing BRCA1, BRCA2 and PALB2. Interacts with BRCA1 and this interaction is essential for its function in HRR. Interacts with RAD51, BRCA2, RAD51AP1 and MORF4L1/MRG15.

Subcellular Location:
Nucleus. Note=Colocalizes with BRCA2 in nuclear foci.

DISEASE:
Breast cancer (BC) [MIM:114480]: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Breast cancer susceptibility is strongly associated with PALB2 truncating mutations. Conversely, rare missense mutations do not strongly influence breast cancer risk (PubMed:22241545).
Fanconi anemia complementation group N (FANCN) [MIM:610832]: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. Note=The disease is caused by mutations affecting the gene represented in this entry.
Pancreatic cancer 3 (PNCA3) [MIM:613348]: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue. Note=The disease is caused by mutations affecting the gene represented in this entry.

Similarity:
Contains 7 WD repeats.

Database links:

Entrez Gene: 79728 Human

Entrez Gene: 233826 Mouse

Entrez Gene: 293452 Rat

Omim: 610355 Human

SwissProt: Q86YC2 Human

SwissProt: Q3U0P1 Mouse

Unigene: 444664 Human

Unigene: 38348 Mouse

Unigene: 43638 Rat



Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

BRCA1,BRCA2和其他已經(jīng)確定的易感性基因,只能解釋不到一半的乳腺癌已知遺傳性易感特征,芬蘭科學(xué)家對(duì)113個(gè)有乳腺癌患者的家族進(jìn)行了研究。他們?cè)冢硞€(gè)家族中發(fā)現(xiàn)了一種名為PALB2的基因,這種基因出現(xiàn)缺陷與家族成員患乳腺癌關(guān)系密切。PALB2基因與BRCA2基因在DNA修復(fù)中發(fā)生作用,新發(fā)現(xiàn)的突變會(huì)削弱這一功能。
研究結(jié)果表明,PALB2基因出現(xiàn)缺陷使這些家族成員患乳腺癌的危險(xiǎn)增加3倍。另外,這一基因出現(xiàn)缺陷也使這些家族的男性成員患前列腺癌的危險(xiǎn)增加。
版權(quán)所有 2004-2026 www.www.p2b3.cn 北京博奧森生物技術(shù)有限公司
通過國(guó)際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號(hào): 00124Q34771R2M/1100
通過國(guó)際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號(hào): CQC24QY10047R0M/1100
京ICP備05066980號(hào)-1         京公網(wǎng)安備110107000727號(hào)
姚安县| 开封市| 拉孜县| 武山县| 山东| 新乡市| 台前县| 博罗县| 衡东县| 海城市| 建水县| 濮阳县| 丽水市| 石柱| 筠连县| 海林市| 年辖:市辖区| 汶川县| 堆龙德庆县| 大新县| 奎屯市| 贵南县| 夏河县| 如皋市| 永泰县| 平舆县| 磐安县| 延安市| 商城县| 札达县| 霞浦县| 镇江市| SHOW| 泊头市| 清新县| 建始县| 乐亭县| 宣威市| 新兴县| 曲阳县| 潞西市|